Overall rank by patents
#26,366
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 10 technology areas, active 2016–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
Gnosis holds 10 US patents across 10 technology areas, rank #26,366 of 50,000 tracked assignees.
Gnosis SPA has been granted 10 US utility patents between 2016 and 2020, placing Gnosis SPA at rank #26,366 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.5 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Gnosis SPA is one of the more focused assignees in the PatentsView dataset. By volume, Gnosis sits between Global Biolife Inc. (10 patents, rank #26,362) and Grace TECH Llc (10 patents, rank #26,370) - the closest US assignees by grant volume. The composite Innovation Score of 26.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 7 in the 2015–2019 window, a -57% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Gnosis SPA's 11.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Gnosis SPA against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
GLOBAL BIOLIFE INC.
10 patents
GLOBAL ENERGY INTERCONNECTION RESEARCH INSTITUTE CO., LTD.
10 patents
GLOBAL SAFETY TEXTILES GMBH
10 patents
GM Pharmaceuticals, Inc.
10 patents
GOLIATHTECH INC.
10 patents
GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE ADMINISTRATOR OF THE U.S. ENVIRONMENTAL PROTECTION AGENCY
10 patents
GOWell International, LLC
10 patents
GRACE TECH LLC
10 patents
GNOSIS SPA
10 patents
What this shows Gnosis holds 10 patents at rank #26,366, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Gnosis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
26 Top 80% higher than 20% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 10.0% |
| 2017 | 4 | 40.0% |
| 2018 | 1 | 10.0% |
| 2019 | 1 | 10.0% |
| 2020 | 3 | 30.0% |
Top 10 of 10 technology areas
Overall rank by patents
#26,366
Across all tracked assignees
26.4 out of 100
How to use this portfolio
Gnosis's 10 grants land it in the top 80% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.